SLC5A2 and dementia: Incident all-cause dementia was comparable between those on GLP1 receptor agonists versus SGLT2 inhibitors in the intention-to-treat analysis (HR [95% CI]: 0.98 [0.87–1.11]; Fig. 2E) and in the as-treated analysis (HR [95% CI]: 1.07 [0.85–1.36]; Fig. 2F).